Want to see GB:HEMO full AI Analyst Report?
HEMO Stock Chart & Stats
568.00 p
-12.50 p(-3.23%)
At close: 4:00 PM EST
568.00 p
-12.50 p(-3.23%)
Day’s Range― - ―
52-Week Range124.00 p - 1,800.00 p
Previous CloseN/A
Volume114.00
Average Volume (3M)113.41K
Market Cap
£52.36M
Enterprise Value53.32M
Total Cash (Recent Filing)£1.59M
Total Debt (Recent Filing)£2.00M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.21
Shares Outstanding6,799,961
10 Day Avg. Volume30,447
30 Day Avg. Volume113,406
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)21.26
Price to Sales (P/S)0.00
P/FCF Ratio-7.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Hematology/oncology PipelineA concentrated R&D focus on hematology and oncology provides durable scientific differentiation and clearer clinical development priorities. Specialization can improve trial design, partnerability, and eventual market positioning versus broader-play biotechs, supporting long-term value creation if candidates advance.
Declining Absolute Debt LevelA multi-year reduction in total debt meaningfully lowers financing pressure for a pre-revenue biotech and modestly extends operational runway. Sustained deleveraging improves negotiating leverage with partners and lenders and reduces downside insolvency risk versus prior years.
Reduced Operating Cash Burn In 2025An observable reduction in operating cash outflow indicates improved cost discipline or efficiency in R&D spending. For a loss-making, pre-revenue company this trend materially extends the time available to reach clinical milestones or secure partnerships before requiring additional funding.
Bears Say
Pre-revenue Business ModelLack of any revenue means the company has no proven commercial cash generation and remains fully dependent on external financing. That structural reliance increases dilution risk, limits reinvestment capacity, and raises uncertainty about sustainable long-term operations absent successful product commercialization or licensing.
Widening Net LossesEscalating annual losses signal rising consumption of capital and deeper negative profitability trends. For a company without revenue, expanding losses accelerate depletion of equity and cash buffers, pressuring management to raise funds more frequently and potentially at unfavorable terms, harming long-term shareholder economics.
Elevated Leverage And Eroded EquityHigh leverage combined with a shrinking equity base reduces financial flexibility for trial funding and business development. In a pre-revenue biotech, this structural imbalance increases refinancing and covenant risk, narrows strategic options, and amplifies downside if clinical programs slip or require larger capital injections.
HemoGenyx Pharmaceuticals Plc News
HEMO FAQ
What was HemoGenyx Pharmaceuticals Plc’s price range in the past 12 months?
HemoGenyx Pharmaceuticals Plc lowest share price was 124.00 p and its highest was 1800.00 p in the past 12 months.
What is HemoGenyx Pharmaceuticals Plc’s market cap?
HemoGenyx Pharmaceuticals Plc’s market cap is £52.36M.
When is HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date?
HemoGenyx Pharmaceuticals Plc’s upcoming earnings report date is Sep 24, 2026 which is in 80 days.
How were HemoGenyx Pharmaceuticals Plc’s earnings last quarter?
HemoGenyx Pharmaceuticals Plc released its earnings results on Apr 30, 2026. The company reported -0.787 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.787 p.
Is HemoGenyx Pharmaceuticals Plc overvalued?
According to Wall Street analysts HemoGenyx Pharmaceuticals Plc’s price is currently Overvalued.
Does HemoGenyx Pharmaceuticals Plc pay dividends?
HemoGenyx Pharmaceuticals Plc does not currently pay dividends.
What is HemoGenyx Pharmaceuticals Plc’s EPS estimate?
HemoGenyx Pharmaceuticals Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HemoGenyx Pharmaceuticals Plc have?
HemoGenyx Pharmaceuticals Plc has 6,799,961 shares outstanding.
What happened to HemoGenyx Pharmaceuticals Plc’s price movement after its last earnings report?
HemoGenyx Pharmaceuticals Plc reported an EPS of -0.787 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.735%.
Which hedge fund is a major shareholder of HemoGenyx Pharmaceuticals Plc?
Currently, no hedge funds are holding shares in GB:HEMO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HemoGenyx Pharmaceuticals Plc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
117.23%
12-Months-Change
Fundamentals
Return on Equity
-2807.75%
Trailing 12-Months
Asset Growth
-0.85%
Trailing 12-Months
Company Description
HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a preclinical biotechnology company dedicated to the discovery, advancement, and commercialization of innovative therapies for various blood diseases. The firm's pipeline is heavily focused on creating novel solutions for the bone marrow and hematopoietic stem cell (BM/HSC) transplant sector. Key developments include a CDX bi-specific antibody, engineered to target challenging conditions such as relapsed/refractory acute myeloid leukaemia (R/R AML), specific forms of acute lymphoblastic leukaemia, and myelodysplastic syndrome, aiming to replace traditional chemotherapy or radiation for transplant conditioning. Also under development is HEMO-CAR-T therapy, which utilizes chimeric antigen receptor T-cells to effectively identify and destroy human acute myeloid leukaemia cells in laboratory and in vivo settings. Additionally, the company is advancing Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapeutic specifically for BM/HSC transplant procedures. Founded in 2012, Hemogenyx Pharmaceuticals is headquartered in London, United Kingdom.
Technical Analysis
ImmuPharma
―
Open Orphan Plc
―
Poolbeg Pharma Ltd.
―
Arecor Therapeutics PLC
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---